Mazars has boosted its remedies and antitrust compliance expertise with the acquisition of CompetitionRx. The addition will, according to Mazars, strengthen its ability to act across merger control, state aid and antitrust cases.
CompetitionRx is a specialist provider of monitoring trustee services and compliance advice in merger control proceedings, competition, and state aid investigations. The firm operates from its offices in London, Brussels and Paris, and works with clients across Europe, China, the US and South America.
In line with its ambition to complement its existing capabilities in state aid and merger control cases and to expand its expertise footprint, consulting firm Mazars decided to acquire CompetitionRx. “This is an important strategic investment for Mazars. We are committed to increasing our global footprint in monitoring trustee services and related areas; it’s a part of our business with great potential,” explains Rudi Lang, Mazars’ Global Head of Monitoring Trustee Services.
Following the acquisition, CompetitionRx Director Justin Menezes has been appointed Mazars Partner and will continue the development of Mazars’ trustee services. “I am delighted to be joining Mazars and excited by the opportunities this brings to develop our business globally,” comments Menezes.
Founder and Managing Director Thomas Hoehn will also stay on to support the team. “We are delighted to welcome Justin, Tom and the rest of the CompetitionRx team to Mazars. Their skills and experience will be a major asset in the continued development of our capabilities – we look forward to a successful future together,” concludes Lang.